The research community in Brazil is still waiting for a patent system aligned with international standards.
Plagued with an average 10-year backlog, red tape and a lack of examining guidelines, these applicants want a world-class patent system.
The 1999 amendment to the Brazilian patent law created prior approval, an additional patentability requirement for applications claiming pharmaceutical products or processes. This patentability requirement is not examined by the Brazilian patent office (INPI) but by ANVISA, the Brazilian food and drug administration.
The system has never worked properly. 2013 brought changes in the procedures between INPI and ANVISA that worsen the situation.
To continue reading, you need a subscription to WIPR. Start a subscription to WIPR for £455.
In-house feature articles, the archive and expert comment require a paid subscription. Subscribe now.
Want to give it a try? We are offering a two week free trial to the WIPR website – register and select “Free Trial” to begin access to the full WIPR archive and read the latest news, features and expert comment. Begin your free trial here.
Is your 2 week free trial about to end? Upgrade to a 12 month subscription for £455 now.
If you have already subscribed please login.
If you have any technical issues please email James Lynn on email@example.com.
patent, INPI, Brazil, WTO TRIPS, ANVISA